within Pharmacolibrary.Drugs.ATC.M;

model M01AX01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.35,
    Cl             = 2.9166666666666666e-05,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.002,
    Tlag           = 1800
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M01AX01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Nabumetone is a non-steroidal anti-inflammatory drug (NSAID) used for the treatment of pain and inflammation in conditions such as osteoarthritis and rheumatoid arthritis. It is a prodrug that is converted in the liver to its active form, 6-methoxy-2-naphthylacetic acid (6-MNA). It is an approved medication still in use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for healthy adult volunteers after oral administration of nabumetone.</p><h4>References</h4><ol><li><p>Hedner, T, et al., &amp; Ekbom, A (2004). Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. <i>Drugs</i> 64(20) 2315–2345. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200464200-00004&quot;>10.2165/00003495-200464200-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15456329/&quot;>https://pubmed.ncbi.nlm.nih.gov/15456329</a></p></li><li><p>Brier, ME, et al., &amp; Aronoff, GR (1995). Population pharmacokinetics of the active metabolite of nabumetone in renal dysfunction. <i>Clinical pharmacology and therapeutics</i> 57(6) 622–627. DOI:<a href=&quot;https://doi.org/10.1016/0009-9236(95)90224-4&quot;>10.1016/0009-9236(95)90224-4</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7781261/&quot;>https://pubmed.ncbi.nlm.nih.gov/7781261</a></p></li><li><p>Boelaert, JR, et al., &amp; Cooper, DL (1987). Nabumetone pharmacokinetics in patients with varying degrees of renal impairment. <i>The American journal of medicine</i> 83(4B) 107–109. DOI:<a href=&quot;https://doi.org/10.1016/0002-9343(87)90606-1&quot;>10.1016/0002-9343(87)90606-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3687998/&quot;>https://pubmed.ncbi.nlm.nih.gov/3687998</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M01AX01;
